In today’s recent session, 3.46 million shares of the Checkpoint Therapeutics Inc (NASDAQ:CKPT) have been traded, and its beta is 1.13. Most recently the company’s share price was $4.22, and it changed around $0.03 or 0.63% from the last close, which brings the market valuation of the company to $366.91M. CKPT at last check was trading at a discount to its 52-week high of $4.50, offering almost -6.64% off that amount. The share price’s 52-week low was $1.75, which indicates that the recent value has risen by an impressive 58.53% since then. We note from Checkpoint Therapeutics Inc’s average daily trading volume that its 10-day average is 1.38 million shares, with the 3-month average coming to 2.82 million.
Checkpoint Therapeutics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.33. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 2 recommended CKPT as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Checkpoint Therapeutics Inc is expected to report earnings per share of -0.02 for the current quarter.
Checkpoint Therapeutics Inc (NASDAQ:CKPT) trade information
Instantly CKPT has been showing a green trend so far today with a performance of 0.63% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 4.21 on recent trading daydecreased the stock’s daily price by -0.24%. The company’s shares are currently up 31.76% year-to-date, but still up 1.36% over the last five days. On the other hand, Checkpoint Therapeutics Inc (NASDAQ:CKPT) is 2.59% up in the 30-day period. We can see from the shorts that 3.8 million shares have been sold at a short interest cover period of 2.19 day(s).
The consensus price target as assigned by Wall Street analysts is $4.1, which translates to bulls needing to decrease their stock price by -2.93% from its current value. Analyst projections state that CKPT is forecast to be at a low of $4.1 and a high of $4.1.
Checkpoint Therapeutics Inc (CKPT) estimates and forecasts
The year-over-year growth rate is expected to be 177,529.26%, up from the previous year.
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of 7.28M in revenue for the current quarter. 1 analysts expect Checkpoint Therapeutics Inc to make 29.13M in revenue for the current ending quarter. Analysts predict that the company’s current quarter sales will jump, forecast at 17,663.41%. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 27.34%.
CKPT Dividends
Checkpoint Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-12.
Checkpoint Therapeutics Inc (NASDAQ:CKPT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 14.05% of Checkpoint Therapeutics Inc shares, and 42.18% of them are in the hands of institutional investors. The stock currently has a share float of 49.08%. Checkpoint Therapeutics Inc stock is held by 95.0 institutions, with ARMISTICE CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 6.8608% of the shares, which is about 2.51 million shares worth $5.39 million.
VANGUARD GROUP INC, with 3.6603% or 1.34 million shares worth $2.87 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.09 shares worth $4.61 million, making up 1.27% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held roughly 732.7 shares worth around $3.09 million, which represents about 0.85% of the total shares outstanding.
